YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Not one, but two, analysts published new takes on Shattuck Labs (NASDAQ: STTK) in the past few days. Since both prognosticators were optimistic about the clinical-stage biotech's future, investors were cheered enough to buy into its stock.…
* Shattuck Labs press release [https://seekingalpha.com/pr/20614116-shattuck-labs-reports-second-quarter-2026-financial-results-and-recent-business-highlights] (STTK [https://seekingalpha.com/symbol/STTK]): Q2 GAAP EPS of -$0.12 in-line. *…
A new analyst note was the key factor behind the mini-rally in Shattuck Labs (NASDAQ: STTK) stock on the last trading day of the week. The clinical-stage biotech's shares closed the day almost 5% higher, thanks mainly to that research. Ups…
Key Points He was encouraged by the progress of the company's SL-325. This, the biotech's lead drug candidate, is about to enter Phase 2 clinical testing.10 stocks we like better than Shattuck Labs › A new analyst note was the key factor b…
SpaceX initiated, PayPal upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by…
(RTTNews) - Among Friday's notable biotech movers were TherapeuticsMD, which is evaluating a strategic review process; Sensei Biotherapeutics, supported by optimism surrounding a key clinical catalyst expected in the second half of 2026; a…
* Shattuck Labs (STTK [https://seekingalpha.com/symbol/STTK]) priced [https://seekingalpha.com/pr/20546216-shattuck-labs-inc-announces-pricing-of-75-million-public-offering] its previously announced public offering to raise ~$75M in gross…
AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal…
AUSTIN, Texas and DURHAM, N.C., June 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-…
Shattuck Labs, Inc. (NASDAQ:STTK) is one of the best performing small cap stocks so far in 2026. Cantor Fitzgerald initiated coverage of Shattuck Labs, Inc. (NASDAQ:STTK) with an Overweight rating on April 27, telling investors in a resear…
Shattuck Labs(NASDAQ: STTK) was an outlier in the healthcare sector this week, thanks mostly to a very well-received earnings report and business update. Over the five trading days, according to data compiled by S&P Global Market Intellige…
Key Points The biotech published its final earnings report and business covering 2025. It posted a slightly narrower-than-expected net loss for the fourth quarter.10 stocks we like better than Shattuck Labs › Shattuck Labs(NASDAQ: STTK) wa…
(RTTNews) - Shattuck Labs, Inc. (STTK) has reported fourth-quarter and full-year 2025 financial results and outlined progress across its pipeline targeting the TL1A/DR3 pathway, a central driver of immune dysregulation and inflammation. Fo…
Shattuck Labs, Inc. AUSTIN, TX and DURHAM, NC, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosi…
[Republican Politics and Wall Street] Douglas Rissing Shares of Shattuck Labs (STTK [https://seekingalpha.com/symbol/STTK]) climbed on Wednesday after Piper Sandler launched its coverage with an Overweight rating and a $15 per share target…
[Panoramic skyline of New York city at sunset, USA] Nico De Pasquale Photography Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact st…
Key Points An analyst's recommendation upgrade had a major impact on investor sentiment. It's now a buy, according to the pundit.10 stocks we like better than Shattuck Labs › A recommendation upgrade from an analyst at the beginning of Dec…
With strong three-month performance and significant upside potential, Shattuck Labs, Inc. (NASDAQ:STTK) secures a spot on our list of the 12 hot penny stocks to invest in right now.Analyst Confidence Upbeat on Shattuck Labs (STTK) Amid SL-…
–First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers – – Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 – – Appointments of Dan Baker, M.D., and Mona Ashiya,…
AUSTIN, TX and DURHAM, NC, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptor…
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE…
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT STI [https://www.chartmill.com/stock/quote/STI/profile] 86.59% SOLIDION TECHNOLOGY INC'S (NASDA…
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT STI [https://www.chartmill.com/stock/quote/STI/p…
Shattuck Labs, Inc. — Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma ca…
— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma cash and cash equivale…
– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases – – The Company is on track to dose the first partic…
– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 – – On track to dose first participant in Phase 1 clinical trial for SL-325 in Q3 20…
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session. [topmovers] GAINERS TICKER CHANGE COMMENT YMAB [https://www.cha…
Discover the most active stocks in Tuesday's session. Stay informed about the stocks that are generating the most trading volume! [mostactive] MOST ACTIVE STOCKS TICKER CHANGE COMMENT ADAP [https://www.chartmill.com/stock/quote/ADAP/profil…
Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT YMAB [https://www.chartmill.com/stock/quote/YMAB/profile] 103.0% Y-MABS THERAP…
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change SolarMax Technology Inc. 215,178,273 2.50 1.57 2.025 +1.095 LOBO EV TECHNO…
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT SMXT [https://www.chartmill.com/stock/quote/SMXT/profi…
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. [premarket] GAINERS TICKER CHANGE COMMENT AIP [https://www.chartmill.com/stock/quote/AIP/profile] 61.59…
– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease – – Pro forma cash and cash equivalents from aggregate proc…
[Business and stock exchange data on the screen.] Torsten Asmus Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next w…